An update on LDL apheresis for nephrotic syndrome.
Rupesh RainaVinod KrishnappaPublished in: Pediatric nephrology (Berlin, Germany) (2018)
Low-density lipoprotein (LDL) apheresis has been used increasingly in clinical practice for the treatment of renal diseases with nephrotic syndrome (NS), specifically focal segmental glomerulosclerosis (FSGS). Persistent hyperlipidemia for prolonged periods is nephrotoxic and leads to chronic progressive glomerular and tubulointerstitial injury. Effective management of hyperlipidemia with HMG-CoA reductase inhibitors or LDL apheresis in drug-resistant NS patients may prevent the progression of renal disease and, in some patients, resolution of NS symptoms. Available literature reveals beneficial effects of LDL apheresis for NS refractory to drug therapy. Here we update on the current understanding of lipid nephrotoxicity and application of LDL apheresis to prevent progression of renal diseases.
Keyphrases
- low density lipoprotein
- drug resistant
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- dengue virus
- clinical practice
- systematic review
- prognostic factors
- high fat diet
- emergency department
- metabolic syndrome
- patient reported outcomes
- zika virus
- depressive symptoms
- combination therapy
- bone marrow
- endothelial cells